RRML - Extended panel of biomarkers for long term monitoring of effectiveness of 3 direct antiviral regimen in HCV genotype 1b infection: results from a Romanian infectious disease hospital
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12


Advanced search


Top 10 downloaded articles
- February 2024 -
 
Anti-thyroid peroxidase (TPO) ... 18
Romanian Review of Laboratory ... 17
Recomandarea comună EFLM-COLA... 13
Approaching Risk Management in... 12
Identification of shared hub g... 12
Challenges in prophylactic the... 12
Monocyte to high-density lipop... 9
Atellica CH 930 chemistry anal... 8
Understanding the key differen... 7
Clinical application value of ... 7

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 29(1)/2021 DOI:10.2478/rrlm-2020-0040
XML
TXT

Research article

Extended panel of biomarkers for long term monitoring of effectiveness of 3 direct antiviral regimen in HCV genotype 1b infection: results from a Romanian infectious disease hospital

Ioana-Alina Harja-Alexa, Luca Catalina Mihaela, Carmen Doina Manciuc, Andrei Vata, Aida Badescu, Mihnea-Eudoxiu Hurmuzache, Alexandra Mirela Ciocan, Ioana Maria Hunea, Luminita-Smaranda Iancu

Correspondence should be addressed to: Ioana-Alina Harja-Alexa

Abstract:

Background: Hepatitis C virus can be eradicated with antiviral therapy, thus reducing the risk of disease progression and death associated with the final stage of liver disease. Methods: 241 patients received PrOD+RBV for 12 weeks. Clinical and laboratory data were assessed at baseline, week 4, 8, 12 (end of treatment, EOT), and 12 weeks after therapy (sustained virological response, SVR). Subsequently, biological and virological measurements were performed at least 48 weeks after obtaining SVR12 in responder patients. Results: Per protocol SVR12 rate was 97,6%. Severe adverse events were reported in 3 patients (1.24%) and led to treatment discontinuation (liver decompensation). One 58-year-old patient who completed the treatment died before SVR evaluation due to acute mesenteric ischemia (not related to antiviral therapy). Baseline total bilirubin above 2 mg/dl can be considered a predictive factor for non-response to PrOD+RBV treatment (p = 0.004). Of the 30 patients evaluated at least 48 weeks after SVR no one presented relapses, with no statistically significant differences in biological parameters changes and no adverse events were noted during the 48-week follow up period. Conclusion: Our study revealed the high effectiveness and good safety profile of PrOD +RBV in patients with genotype-1b HCV compensated cirrhosis (Child Pugh A) which were maintained during a 48-week period after treatment finalization.

Keywords: hepatitis C virus, compensated cirrhosis, direct-acting antiviral agents

Received: 4.9.2020
Accepted: 15.11.2020
Published: 31.12.2020

 
  PDF Download full text PDF
(433 KB)
     
 
How to cite
Harja-Alexa IA, Mihaela LC, Manciuc CD, Vata A, Badescu A, Hurmuzache ME, et al. Extended panel of biomarkers for long term monitoring of effectiveness of 3 direct antiviral regimen in HCV genotype 1b infection: results from a Romanian infectious disease hospital. Rev Romana Med Lab. 2021;29(1):93-103. DOI:10.2478/rrlm-2020-0040